Does Gleason score (GS) predict efficacy of abiraterone acetate (AA) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)? An analysis of AA phase 3 trials Meeting Abstract

  

Authors:	Fizazi, K.; Flaig, T. W.; Ohlmann, C. H.; Scher, H. I.; de Bono, J. S.; Rathkopf, D. E.; Ryan, C. J.; Kheoh, T. S.; Li, J. H.; Todd, M. B.; Griffin, T. W.; Molina, A.; Stöckle, M.
Abstract Title:	Does Gleason score (GS) predict efficacy of abiraterone acetate (AA) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)? An analysis of AA phase 3 trials
Meeting Title:	2014 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium
Journal Title:	Journal of Clinical Oncology
Volume:	32
Issue:	Suppl. 4
Meeting Dates:	2014 Jan 30-Feb 1
Meeting Location:	San Francisco, CA
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2014-02-01
Language:	English
ACCESSION:	WOS:000335318100023
PROVIDER:	wos
DOI:	10.1200/jco.2014.32.4_suppl.20
Notes:	Meeting Abstract: 20 -- Genitourinary Cancers Symposium -- JAN 30-FEB 01, 2014 -- San Francisco, CA -- S -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/52483